HNC: Human Neural Circuits Electrophysiology During Cognition

NCT05962424 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-04-22

No results posted yet for this study

Summary

The purpose of this study is to understand how ketamine brings about dissociative symptoms.

Conditions

  • Psychiatric Disorder

Interventions

DRUG

Ketamine Hydrochloride

Ketamine is an FDA-approved dissociative anesthetic.

Sponsors & Collaborators

Principal Investigators

  • Karl Deisseroth, MD, PhD · Stanford University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-05
Primary Completion
2030-09-01
Completion
2030-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05962424 on ClinicalTrials.gov